English
Home > Products > 120-93-4

China 120-93-4 Factory

we can easily provide top quality solutions, competitive value and best client company. Our destination is "You come here with difficulty and we provide you a smile to take away" for 120-93-4,CAS NO 120-93-4,2-Imidazolidone,Ethylene Urea, We hope to ascertain far more small business interactions with prospects all over the world.
120-93-4, For many years, we have now adhered to the principle of customer oriented, quality based, excellence pursuing, mutual benefit sharing. We hope, with great sincerity and good will, to have the honor to help with your further market.

Related Products

Hot Products

  • 2-Chloro-3-(trifluoromethyl)pyridine

    2-Chloro-3-(trifluoromethyl)pyridine

    Product Name:2-Chloro-3-(trifluoromethyl)pyridine
    Molecular Formula:C6H3ClF3N
    Molecular Weight:181.54
    CAS Registry Number:65753-47-1
  • 4,5-Dimethoxy-1-cyanobenzocyclobutane

    4,5-Dimethoxy-1-cyanobenzocyclobutane

    Product Name:4,5-Dimethoxy-1-cyanobenzocyclobutane
    Molecular Formula:C11H11NO2
    Molecular Weight:189.21
    CAS Registry Number:35202-54-1
  • (R)-(+)-2-Tetrahydrofuroic acid

    (R)-(+)-2-Tetrahydrofuroic acid

    Product Name:(R)-(+)-2-Tetrahydrofuroic acid
    Molecular Formula:C5H8O3
    Molecular Weight:116.12
    CAS Registry Number:87392-05-0
  • 1,1,7-trichloro-1-hepten-3-one

    1,1,7-trichloro-1-hepten-3-one

    Product Name:1,1,7-trichloro-1-hepten-3-one
    Molecular Formula:C7H9Cl3O
    Molecular Weight:215.5
    CAS Registry Number:158355-41-0
  • Ezetimibe

    Ezetimibe

    Product Name:Ezetimibe
    Molecular Formula:C24H21F2NO3
    Molecular Weight;409.43
    CAS Registry Number;163222-33-1
  • 2-(2-Oxo-butyl)-cyclohexane-1,3-dione

    2-(2-Oxo-butyl)-cyclohexane-1,3-dione

    Product Name:2-(2-Oxo-butyl)-cyclohexane-1,3-dione
    Molecular Formula:C10H14O3
    Molecular Weight:182.22
    CAS Registry Number:24836-98-4
  • Related Blog
  • Reviews

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • How to find the best China API manufacturer?

    Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 120-93-4

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept